Breaking News
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
December 14, 2017 - Minority people less likely to see dermatologist for psoriasis treatment
December 14, 2017 - Study indicates decline in use of chemotherapy for early stage breast cancer patients
December 14, 2017 - Chagas disease presents real public health problem to Canadians
December 14, 2017 - Experts call for rigorous clinical trials in use of experimental fetal therapy
December 14, 2017 - Lactic acid bacteria can offer protection against subtypes of influenza A virus
December 14, 2017 - Tapeworm drug could provide new hope for patients with Parkinson’s disease
December 14, 2017 - Parkinson’s progression delayed through high-intensity exercise, study says
December 14, 2017 - Researchers discover potential regulator essential for killer T cells to reside in tumors
December 14, 2017 - Tailor-made protein combats several kinds of pathogenic bacteria
December 14, 2017 - Hidden genes hold blueprints for designing new anti-cancer drugs
December 14, 2017 - Male virgins still at risk for acquiring HPV, study finds
December 14, 2017 - Study reveals novel molecular targets to improve chemotherapy’s efficiency against leukemia
December 14, 2017 - Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
December 14, 2017 - AHA: Hospital QI Initiative Fails to Budge Outcomes in India
December 14, 2017 - Scientists observe tremors associated with Parkinson’s disease in fruit flies
December 14, 2017 - Newly discovered molecular chaperones may soon be part of therapies for Huntington’s disease
December 14, 2017 - Performing surgery on virtual patient could provide valuable insight into consequences
December 13, 2017 - New insights into mosquito sex protein could provide strategies to control diseases
December 13, 2017 - Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
December 13, 2017 - Step Into Sunshine | Medpage Today
December 13, 2017 - Poor Prognosis for Diabetic Foot Sores: MedlinePlus Health News
December 13, 2017 - Exercise alone does not lead to weight loss in women—in the medium term
December 13, 2017 - Researchers use new approach to identify casual mechanisms in depression
December 13, 2017 - Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test
December 13, 2017 - Study finds barriers to stem cell transplant use among multiple myeloma patients from minority groups
December 13, 2017 - Scientists discover how axons in developing visual system stabilize their connections
December 13, 2017 - Novel compound inhibits mycomembrane biosynthesis and kills tuberculosis bacteria
December 13, 2017 - FDA Launches New Tool for Sharing Information That Allows Doctors to Better Manage Antibiotic Use
December 13, 2017 - Evolocumab Wins FDA Approval for Stand-Alone CVD Prevention
December 13, 2017 - Powerful Clot-Busting Drugs Not Useful After Leg Blockages: Study: MedlinePlus Health News
December 13, 2017 - The fight against obesity: To tax or not to tax?
December 13, 2017 - Isolation during holidays can impact health of seniors
December 13, 2017 - Specialized physiotherapy provides many benefits for patients with Parkinson’s disease
December 13, 2017 - Pairing immunotherapy drug with chemotherapy proves beneficial for relapsed acute myeloid leukemia
December 13, 2017 - Researchers find link between brain structure and hallucination proneness, musical aptitude
December 13, 2017 - Radiation responsive molecules derived from horse chestnuts aid cancer imaging
December 13, 2017 - New Gene Therapy May Be Cure for ‘Bubble Boy’ Disease
December 13, 2017 - MorningBreak: Insurance Driving Drug Prices? Crunch Time for ACA; The ‘Other’ Drug Problem
December 13, 2017 - Are Stents Really Useless After Chest Pain? Cardiologists Not Sure: MedlinePlus Health News
December 13, 2017 - Can you train yourself to develop ‘super senses’?
December 13, 2017 - Cellular self-digestion process plays role in development of autoimmune diseases
December 13, 2017 - E-cigarette use among youth leads to smoking as adults finds study
December 13, 2017 - New nanomaterial could enable new types of chemical processes in pharma, materials and chemical industries
December 13, 2017 - Another CGRP Drug Gains Ground in Migraine
December 13, 2017 - Trigger for most common form of vision loss discovered
December 13, 2017 - Study reveals link between estrogen and infertility
December 13, 2017 - Researchers suggest role for MKL1 protein in development of inflammatory bowel disease
Pioneering research project aims to develop better diagnostic tests for NAFLD

Pioneering research project aims to develop better diagnostic tests for NAFLD

image_pdfDownload PDFimage_print

A pioneering European research project aims to lead to new diagnostic tests to assess patients with non-alcoholic fatty liver disease (NAFLD) and identify those most at risk for developing severe inflammation and liver scarring.

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA). Their common goals are developing, validating and qualifying better biomarkers for testing NAFLD.

The €34 million project is co-ordinated by Newcastle University, UK, working closely with the lead EFPIA partner, Pfizer Ltd. LITMUS will include 47 international research partners based at leading international universities and some of the world’s largest pharmaceutical companies.

Affecting 20 – 30 % of the population worldwide, NAFLD is caused by a build-up of fat in the liver cells, which leads to inflammation, scarring of the liver and ultimately cirrhosis. It is strongly linked to obesity and type 2 diabetes.

Although many people have NAFLD, less than one in 10 will come to harm as a result1. The challenge is to identify those people that will be most severely affected and are going to progress to liver cirrhosis or cancer so that appropriate care can be provided earlier. At present this requires a liver biopsy, which can only be done in specialist hospitals, so there is a need for better diagnostic tools.

Professor Quentin Anstee, from Newcastle University’s Institute of Cellular Medicine and Consultant Hepatologist at Newcastle Hospitals NHS Foundation Trust, is co-ordinating the LITMUS consortium.

He said: “Non-alcoholic fatty liver disease is already the most common underlying cause of liver transplant in the USA and, with the obesity epidemic in Europe, we are very close behind.

“LITMUS will unite clinicians and academic experts from centres across Europe with scientists from the leading pharmaceutical companies, all working together to develop and validate new highly-accurate blood tests and imaging techniques that can diagnose the severity of liver disease, predict how each patient’s disease will progress and monitor those changes, better or worse, as they occur.

“Lack of easy and accurate diagnostic tests means that many patients go undiagnosed until late in the disease process. It has also held-back efforts to develop new medical treatments for NAFLD. Availability of better diagnostic tests will help us to target care at an early stage of disease to the people who are going to be most severely affected. It will also help us to develop more effective medical treatments for NAFLD and to run the clinical trials that the regulatory agencies need so that they can licence these medicines to be prescribed by doctors.”

Professor Chris Day, Vice-Chancellor and President, Newcastle University, who is himself a Consultant Hepatologist with an international reputation and part of the research team, added: “Tackling Non-alcoholic fatty liver disease is a major public health challenge and the award of such a large grant from the EU, allowing us to bring together pharma and academia in this way, gives us real hope of making significant advances in the diagnosis and treatment of this increasingly common and often devastating disease.”

Julia Brosnan, Senior Director of External Collaborations & Scientific Alliances, Pfizer, who also serves as the industry project lead for LITMUS, said: “This is an exciting project and we look forward to working with the other LITMUS partners to develop new diagnostic tests for NAFLD, which is too often undiagnosed in patients. We hope the results of this project will help change that.”

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Living with NAFLD – Yvonne’s story

Yvonne Gray, 62, was diagnosed with NAFLD in 2011. A retired headteacher who lives in Fulwell, Sunderland, she is now a governor of the national adult liver patient support group, LIVErNORTH:

“I do consider myself really fortunate in that it was by chance my liver disease was eventually diagnosed, when my “mildly abnormal” liver function tests were picked up by a consultant treating me for a Vitamin D deficiency and he then referred me to a hepatologist.

“By the time I was referred to the Freeman Hospital Liver Unit in Newcastle I had Non-Alcoholic Fatty Liver Disease, specifically NASH, Stage 3 Liver Disease with significant fibrosis.

“It is interesting that even now my liver function tests are still presenting as ‘mildly abnormal’, thereby not appearing to trigger any major cause for concern. However, my two liver biopsies say something totally different.

“It is exciting to hear about this new collaboration. I would be delighted if there could be a simple blood test. The alternative, a liver biopsy, can involve a stay in hospital, is uncomfortable and can be painful.”

Source:

http://www.ncl.ac.uk/press/news/2017/11/litmus/

Tagged with:

About author

Related Articles